{"slideshow_credits": null, "snippet": "Genzyme, the American biotechnology unit of the French drug maker Sanofi, is buying a 12 percent stake in Alnylam Pharmaceuticals for $700 million as part of an expanded alliance to develop treatments for rare genetic diseases.", "abstract": "Genzyme, the American biotechnology unit of the French drug maker Sanofi, is buying a 12 percent stake in Alnylam Pharmaceuticals for $700 million as part of an expanded alliance to develop treatments for rare genetic diseases.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Chad", "role": "reported", "lastname": "BRAY", "rank": 1, "organization": ""}], "original": "By CHAD BRAY"}, "web_url": "http://dealbook.nytimes.com/2014/01/13/sanofi-unit-to-buy-700-million-stake-in-rare-disease-company/", "lead_paragraph": null, "headline": {"main": "Sanofi Unit to Buy $700 Million Stake in Rare Disease Company", "kicker": "DealBook"}, "_id": "52d3d67338f0d825af315807", "word_count": "233", "multimedia": [], "pub_date": "2014-01-13T06:52:54Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "glocations", "value": "France", "rank": "1"}, {"name": "glocations", "value": "Massachusetts", "rank": "2"}, {"name": "organizations", "value": "Alnylam Pharmaceuticals Inc", "rank": "1"}, {"name": "organizations", "value": "Genzyme Corp", "rank": "2"}, {"name": "organizations", "value": "Sanofi SA", "rank": "3"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}